生产企业：Oncovita
MVdeltaC is an investigational oncolytic virotherapy developed by Oncovita, based on a genetically modified measles virus (Measovir® platform) with deletion of the C protein virulence gene. It targets CD46-overexpressing cancer cells and activates the RIG-I immune sensor to induce immunogenic cell death, converting cold tumors into hot ones with durable immune memory. Preclinical data show tumor regression and complete remission in mesothelioma, bladder cancer, TNBC, and neuroblastoma models. It has secured Orphan Drug Designation from both FDA and EMA for mesothelioma.
MVdeltaC is an investigational oncolytic virotherapy developed by Oncovita, based on a genetically modified measles virus (Measovir® platform) with deletion of the C protein virulence gene. It targets CD46-overexpressing cancer cells and activates the RIG-I immune sensor to induce immunogenic cell death, converting cold tumors into hot ones with durable immune memory. Preclinical data show tumor regression and complete remission in mesothelioma, bladder cancer, TNBC, and neuroblastoma models. It has secured Orphan Drug Designation from both FDA and EMA for mesothelioma.
MVdeltaC naturally targets CD46, a protein overexpressed on the surface of most cancer cells, granting it tumor specificity. Once inside cancer cells, defective viral RNA molecules massively generated by the modified measles virus activate the RIG-I immune sensor. This triggers strong innate and adaptive immune responses, resulting in potent immunogenic cancer cell death (apoptosis). MVdeltaC converts immunologically 'cold' tumors — those invisible to the immune system — into 'hot,' inflamed targets, and establishes durable anti-tumor immune memory.
MVdeltaC is in preclinical development for multiple solid tumors. In preclinical models (PDX and syngeneic immunocompetent mouse models), MVdeltaC demonstrated potent tumor regression and complete remission (RECIST CR) in mesothelioma, bladder cancer, triple-negative breast cancer (TNBC), and neuroblastoma. It has received Orphan Drug Designation from both the FDA and EMA for mesothelioma. Oncovita is preparing for GMP manufacturing and aims to initiate clinical trials by the end of 2027.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
